251 related articles for article (PubMed ID: 23207283)
1. Immunogenicity and autoimmunity during anti-TNF therapy.
Atzeni F; Talotta R; Salaffi F; Cassinotti A; Varisco V; Battellino M; Ardizzone S; Pace F; Sarzi-Puttini P
Autoimmun Rev; 2013 May; 12(7):703-8. PubMed ID: 23207283
[TBL] [Abstract][Full Text] [Related]
2. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
Ferraro-Peyret C; Coury F; Tebib JG; Bienvenu J; Fabien N
Arthritis Res Ther; 2004; 6(6):R535-43. PubMed ID: 15535831
[TBL] [Abstract][Full Text] [Related]
3. Autoimmunity and anti-TNF-alpha agents.
Atzeni F; Turiel M; Capsoni F; Doria A; Meroni P; Sarzi-Puttini P
Ann N Y Acad Sci; 2005 Jun; 1051():559-69. PubMed ID: 16126996
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.
Emi Aikawa N; de Carvalho JF; Artur Almeida Silva C; Bonfá E
Clin Rev Allergy Immunol; 2010 Apr; 38(2-3):82-9. PubMed ID: 19565360
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody production in patients treated with anti-TNF-alpha.
Atzeni F; Sarzi-Puttini P
Expert Rev Clin Immunol; 2008 Mar; 4(2):275-80. PubMed ID: 20477056
[TBL] [Abstract][Full Text] [Related]
6. Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis.
Thomas SS; Borazan N; Barroso N; Duan L; Taroumian S; Kretzmann B; Bardales R; Elashoff D; Vangala S; Furst DE
BioDrugs; 2015 Aug; 29(4):241-58. PubMed ID: 26280210
[TBL] [Abstract][Full Text] [Related]
7. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
Vermeire S; Noman M; Van Assche G; Baert F; Van Steen K; Esters N; Joossens S; Bossuyt X; Rutgeerts P
Gastroenterology; 2003 Jul; 125(1):32-9. PubMed ID: 12851868
[TBL] [Abstract][Full Text] [Related]
8. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
De Rycke L; Kruithof E; Van Damme N; Hoffman IE; Van den Bossche N; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
[TBL] [Abstract][Full Text] [Related]
9. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Han PD; Cohen RD
Drugs; 2004; 64(16):1767-77. PubMed ID: 15301561
[TBL] [Abstract][Full Text] [Related]
10. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.
Gelinck LB; van der Bijl AE; Beyer WE; Visser LG; Huizinga TW; van Hogezand RA; Rimmelzwaan GF; Kroon FP
Ann Rheum Dis; 2008 May; 67(5):713-6. PubMed ID: 17965123
[TBL] [Abstract][Full Text] [Related]
11. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease.
Nancey S; Blanvillain E; Parmentier B; Flourié B; Bayet C; Bienvenu J; Fabien N
Inflamm Bowel Dis; 2005 Nov; 11(11):986-91. PubMed ID: 16239844
[TBL] [Abstract][Full Text] [Related]
12. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
[TBL] [Abstract][Full Text] [Related]
13. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses.
Menegatti S; Bianchi E; Rogge L
Front Immunol; 2019; 10():382. PubMed ID: 30941119
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
[TBL] [Abstract][Full Text] [Related]
16. Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.
Kiss LS; Lovasz BD; Golovics PA; Vegh Z; Farkas K; Molnar T; Palatka K; Papp M; Mohas A; Szilagyi BK; Fekete SA; Mandel M; Lakatos PL
J Gastrointestin Liver Dis; 2013 Jun; 22(2):135-40. PubMed ID: 23799211
[TBL] [Abstract][Full Text] [Related]
17. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
[TBL] [Abstract][Full Text] [Related]
18. Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressive drugs.
Angelucci E; Cesarini M; Vernia P
Rheumatol Int; 2010 May; 30(7):977-8. PubMed ID: 19551384
[TBL] [Abstract][Full Text] [Related]
19. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
20. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
